210 likes | 442 Views
Differential Diagnosis. L breast has a 2 X 2 cm. hard, non-tender, & movable mass with irregular margins underneath the nipple. Fibroadenoma. Fibroadenomas are the second most common solid tumor after breast cancer and the most common benign tumor in women
E N D
L breast has a 2 X 2 cm. hard, non-tender, & movable mass with irregular margins underneath the nipple Fibroadenoma • Fibroadenomas are the second most common solid tumor after breast cancer and the most common benign tumor in women • composed of stromal and epithelial elements (Benign fibroepithelial neoplasm) • commonly seen in young women(20-30 yr) • Presents as a mass • Usually 2-3 cm in size; well-defined • Single in 80% • Related to estrogen • Not premalignant • The prevalence of fibroadenomas is approximately 8-10% in women older than 40 years. • oval, freely mobile, rubbery masses that may be nonpalpable or palpable. • size varies from smaller than 1 cm in diameter to as large as 15 cm in diameter in the giant forms. • The typical case is the presence of a painless, firm, solitary, mobile, slowly growing lump in the breast of a woman of childbearing years.
L breast has a 2 X 2 cm. hard, non-tender, & movable mass with irregular margins underneath the nipple Fibrocystic Change • Result of prolonged cyclic stimulation of repeated menstrual cycle • 35-50 (premenopausal) • Presentation is tenderness • Pain with multiple cystic lesions/single dominant mass • Not premalignant except those with atypical hyperplasia
L breast has a 2 X 2 cm. hard, non-tender, & movable mass with irregular margins underneath the nipple Phylloides Tumor • Previously called CystosarcomaPhylloides • predominantly benign tumor • invasive- malignant • Mesenchymaland epithelial components • Rapid growth • Rarely metastasizes to the axillary lymph nodes • Phyllodes tumor is the most commonly occurring nonepithelial neoplasm of the breast, although it represents only about 1% of tumors in the breast • It has a smooth, sharply demarcated texture and typically is freely movable. • It is a relatively large tumor, with an average size of 5 cm. However, lesions of more than 30 cm have been reported. • can occur in people of any age; however, the median age is the fifth decade of life.
L breast has a 2 X 2 cm. hard, non-tender, & movable mass with irregular margins underneath the nipple Phylloides Tumor • Patients typically present with a firm, mobile, well-circumscribed, nontender breast mass. • A small mass may rapidly increase in size in the few weeks before the patient seeks medical attention. • Tumors rarely involve the nipple-areola complex or ulcerate to the skin. • Tends to involve the left breast more commonly than the right one. • Overlying skin may display a shiny appearance and be translucent enough to reveal underlying breast veins.
L breast has a 2 X 2 cm. hard, non-tender, & movable mass with irregular margins underneath the nipple Breast Carcinoma • 2nd leading site for both sexes combined; 1st among women • Incidence starts rising steeply at age 30 • 14,043 new cases in 2005 among women • 3rd leading cause of cancer deaths (6,357 breast cancer deaths) • Median survival among females is 60 months. • Clustered microcalcifications – more common here in the Philippines
L breast has a 2 X 2 cm. hard, non-tender, & movable mass with irregular margins underneath the nipple Breast Carcinoma • Hard, solitary, non-tender mass with irregular margins • 40—60 y/o • 40-50% are located in the upper outer quadrant • Since this area contains greater breast volume, including theaxillarytail of Spence • 80% of the time, there are also lesions in the other quadrants • Most common cause of this discharge is breast CA • Bloody nipple discharge • Skin retraction • Involvement of the ligament of Cooper) • Peaud’ orange
Mammography • Examinations of an indeterminate mass that presents as a solitary lesion suspicious of CA • 10% to 50% of cancers detected mammographically are not palpable, 10% to 20% of palpable tumors not detectablemammographically • Although sensitive, not specific • 25% of non-palpable lesions detected are found to be malignant at biopsy • Sine qua non (hallmark): Spiculated density with ill-defined margins (If seen in mammography, consider as a malignancy until proven otherwise) • Features that are suggestive but not diagnostic of cancer includes: • Clustered microcalcifications – more common here in the Philippines • Asymmetric density • Ductalasymmetry • Distortion of skin, nipple & normal breast architecture
Fine Needle Aspiration Biopsy • definitive diagnosis • determination of histopathology
Role of the following? 1. FNAB 2. Mammography 3. Chest x-ray 4. Ultrasound 5. CT scan 6. Bone scan
FNAB • Fine needle aspiration is the easiest and fastest method of obtaining a breast biopsy, and is very effective for women who have fluid filled cysts. • However, the pathological evaluation can be incomplete because the tissue sample is very small. When used alone, about 10% of breast cancers may be missed.
Mammography • Most cost-effective approach for breast cancer screening, however, the sensitivity (67.8%) and specificity (75%) are not ideal. • An X-ray technique that looks for changes in the breast. These appear as changes in the shape of the breast or calcifications. • demonstrated to be an effective tool for the prevention of advanced breast cancer in women at average risk • Mammography often reveals a lesion before it is palpable by clinical breast examination and, on average, 1-2 years before noted by breast self-examination. • Two-view mammography (ie, craniocaudal and oblique) is the imaging method of choice for breast screening
Mammography • Investigation of choice for detecting and classifying microcalcification. • Benign microcalcification is characterized by diffuse scattering and crescentic "tea-cupping." Malignant microcalcification is characterized by isolated clusters, punctate of varying sizes, and a branching or linear pattern. • Mammography is also efficient for helping detect larger patterns of calcification, such as the outlining of calcified arterioles or the coarse patchy calcification of long-standing fibroadenomata.
Chest X-ray • Before treatment begins, a chest x-ray may be done to rule out metastasis of breast cancer the lungs • May be used to assess the heart and lungs before receiving general anesthesia or chemotherapy. • During treatment for breast cancer, chest x-rays may be used in the following situations: • If a person has advanced breast cancer that has spread to the lungs, a chest x-ray is used to check on how the disease is responding to treatment. • For people who develop a fever during chemotherapy, chest x-rays are used to check for the presence of pneumonia. • If a person experiences new shortness of breath in the first few months after radiation therapy, with or without a cough, her doctor may order a chest x-ray to see if the radiation caused any inflammation of the lungs.
Ultrasound • not used on its own as a screening test for breast cancer • used to complement other screening tests. • If an abnormality is seen on mammography or felt by physical exam, ultrasound is the best way to find out if the abnormality is solid (such as a benign fibroadenoma or cancer) or fluid-filled (such as a benign cyst). • cannot determine whether a solid lump is cancerous, nor can it detect calcifications. • guide biopsy needles precisely to suspicious areas in the breast.
Ultrasound • Ultrasonographic features of malignancy include the following: • Poorly defined borders • Heterogeneous internal echoes • Disruption of the tissue layers • Irregular shadowing • Superficial echo enhancement • Depth greater than height • High vascular density and flow rates on Doppler images • Features of benign lesions include the following: • Cyst - Absence of internal echoes, marked deep enhancement • Fibroadenoma - Well-defined borders, well-defined internal echoes, and displacement of tissue planes • Lymph node - Well-defined peripheral blood flow on Doppler images
CT Scan • With contrast, CT scans can help specify lesions with high vascularity. CT scan is also useful for helping detect lung and brain metastases and high axillary and intrathoraciclymphadenopathy. • Right now, CT scans are not used routinely to evaluate the breast • Assess whether or not the cancer has moved into the chest wall. This helps determine whether or not the cancer can be removed with mastectomy. • Examine other parts of the body where breast cancer can spread, such as the lymph nodes, lungs, liver, brain, and/or spine • Generally, CT scans wouldn’t be needed for early-stage breast cancer. • After treatment, CT scans may be used if there is reason to think the breast cancer has spread or recurred outside the breast • May also be used to guide biopsy
Bone Scan • Also called bone scintigraphy, is an imaging test used to determine whether breast cancer has traveled to the bones • a small quantity of radioactive dye is injected into a vein, and a special X-ray is then taken to see if the cancer has gone to bone. • Breast cancer has a predilection to go to bone, where it may lie dormant for many years. A "baseline" scan is obtained for any invasive cancer, to make later scans easier to compare and interpret. • during and after treatment, if patient experiences persistent bone and joint pain, or if a blood test suggests the possibility that the breast cancer has traveled to the bones • If "something" is seen on a bone scan, it may or may not be cancer. Old fractures, inflammation, or infections can make bone scans "light up" in those areas.
Lumpectomy • Excision is diagnostic and therapeutic. • Best suited for the benign or indeterminate lesion where patient preference is removal rather than biopsy with observation